Re: Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial.
Open Access
- 3 July 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 94 (13) , 1029-1030
- https://doi.org/10.1093/jnci/94.13.1029
Abstract
A recent report by Langer et al. (1) in the Journal suggests that cisplatin-based therapy for treatment of advanced non-small-cell lung cancer (NSCLC) should not be denied to fit elderly patients. Their conclusion is based on a retrospective analysis of the Eastern Cooperative Oncology Group (ECOG) 5592 phase III randomized trial of three cisplatin-based regimens, which showed that outcomes did not differ between adult patients younger than 70 years of age and elderly patients 70 years of age or older, i.e., 84 septuagenarians and two octogenarians (15% of the study population).Keywords
This publication has 0 references indexed in Scilit: